Researchers identify beta catenin protein degradation as a therapeutic vulnerability in B cell acute lymphoblastic leukaemia, supporting the repurposing of glycogen synthase kinase 3 beta inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results